Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early versus deferred hormone therapy.

J B Anderson1

  • 1Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. john.anderson@csuh-tr.trent.nhs.uk

European Urology
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time Temperature Heating Effect on Biuret-Positive Water-Extractable Porcine and Bovine Muscle Proteins.

Journal of food protection·2019
Same author

Plasmid-like DNAs in the commercially important mushroom genus Agaricus.

Current genetics·2013
Same author

Flow cytometric analysis of hematologic neoplasia.

Methods in molecular medicine·2011
Same author

Genotyping, gene genealogies and genomics bring fungal population genetics above ground.

Trends in ecology & evolution·2011
Same author

Antidiabetic Diets.

Canadian Medical Association journal·2010
Same author

Mitochondrial Haplotype Influences Mycelial Growth of Agaricus bisporus Heterokaryons.

Applied and environmental microbiology·2006
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
Same journal

Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.

European urology·2026
Same journal

Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026
Same journal

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same journal

Re: Fecal Microbiota Transplantation plus Immunotherapy in Metastatic Renal Cell Carcinoma: The Phase 1 PERFORM Trial.

European urology·2026
See all related articles

The optimal timing for initiating hormone therapy for prostate cancer is debated. Available evidence suggests early treatment may improve survival, but deferred treatment is best for older men with low-volume, well-differentiated cancer.

Area of Science:

  • Oncology
  • Urology
  • Clinical Trials

Background:

  • Hormone therapy is a cornerstone in prostate cancer management.
  • The optimal timing for initiating hormone therapy is not definitively established.
  • Previous randomized studies have yielded debated results.

Purpose of the Study:

  • To review evidence regarding the optimal timing of hormone therapy initiation in prostate cancer.
  • To compare immediate versus deferred hormone treatment strategies.
  • To inform treatment decisions based on prognostic factors and quality of life.

Main Methods:

  • Analysis of randomized studies from Veterans Administration Cooperative Urological Research Group, South Sweden Prostate Cancer Study Group, and Medical Research Council.
  • Consideration of ongoing European Organisation for Research and Treatment of Cancer (EORTC) protocols.

Related Experiment Videos

  • Evaluation of prognostic factors and quality of life indicators.

    • Main Results:

    • Despite study design criticisms, results suggest early hormone therapy may offer advantages in time to progression and survival.
    • Ongoing EORTC studies are expected to provide further insights.
    • Treatment decisions should incorporate prognostic factors and patient quality of life.

    Conclusions:

    • Early hormone therapy is recommended for younger men with poorly differentiated or advanced prostate cancer, and for those with infrequent physician contact.
    • Deferred treatment (watchful waiting) is likely optimal for older men with well-differentiated, low-volume prostate cancer.